RXi Pharmaceuticals announces new chief development officer

RXi Pharmaceuticals has announced that Gerrit Dispersyn, Dr. Med Sc., has been appointed chief development officer.

Dispersyn’s background is in clinical, product and business development. He most recently served as vice president, global head of clinical affairs at Integra Life Sciences, according to a news release from RXi. His position as chief development officer is effective April 24.

RXi’s current chief development officer, Pamela Pavco, PhD, is retiring and will become a member of the company’s scientific advisory board effective May 10.

“I am confident that with Gerrit’s experience, along with the dedicated team at RXi, the company is well positioned for its next phase of growth and development,” Pavco stated in the release. “I look forward to working with Gerrit to ensure a seamless transition.”

Reference: www.rxipharma.com